Bioavailability and dose-dependent anti-tumour effects of 9-cis retinoic acid on human neuroblastoma xenografts in rat by Ponthan, F et al.
Vitamin A and its analogue, retinoic acid (RA), play an important
role in normal cellular differentiation and programmed cell death
(Sucov and Evans, 1995). Retinoids signal through two sets of
closely related intracellular receptors, RAR (retinoic acid receptor
α , β , γ ) and RXR (retinoic X receptor α , β , γ ), which all belong to
the steroid receptor super family (Sucov and Evans, 1995). All-
trans RA (ATRA) binds to RAR with high affinity but does not
bind to RXR, whereas 9-cis RA, an isomer of ATRA, binds and
transactivates both RARs and RXRs (Heyman et al, 1992; Redfern
et al, 1995). 9-cis RA is mainly metabolized in the liver by
cytochrome P450 (CYP 450) to its oxidized form 4-oxo-9-cis RA
(Shirley et al, 1996; Howell et al, 1998). 
Neuroblastoma is the most common extracranial solid tumour in
children. It is characterized by a diversity of clinical behaviour,
ranging from spontaneous remission to rapid tumour progression
and death. Most metastatic neuroblastomas show progression and
poor clinical outcome despite intensive multimodal therapy. This
increases the importance of finding new therapeutic drugs. 
Retinoic acid has been reported to induce differentiation of
neuroblastoma cells in vitro (Sidell, 1982; Reynolds et al, 1991;
Abemayor, 1992; Redfern et al, 1995; Lovat et al, 1997). Recently,
a clinical study from the Children’s Cancer Group (CCG) showed
significantly improved event-free survival for children with high-
risk neuroblastoma when treated with an intermittent schedule of
high-dose 13-cis RA after autologous bone marrow transplantation
(Matthay et al, 1999). 9-cis RA has been shown to induce apop-
tosis in vitro in neuroblastoma cells, using a short-term dosing
schedule of 5 days treatment and subsequent washout and reincu-
bating in RA-free medium (Lovat et al, 1997). Animal studies on
breast cancer have showed promising results using 9-cis RA either
as a single agent or in combination with tamoxifen (Anzano et al,
1994). 
In a previous study, we treated nude rats with human neuroblas-
toma xenograft tumours with 9-cis RA 5 mg day–1 (Ponthan et al,
2001). This experiment showed that 9-cis RA could induce a
significant reduction in tumour growth, but with severe toxic side
effects. The present study was designed to investigate the bioavail-
ability of 9-cis RA in rat. In addition, we wanted to compare two
different dose schedules using 9-cis RA, in order to find a non-
toxic but still tumour-effective treatment regimen. 
MATERIALS AND METHODS 
Chemicals 
The retinoids used in this study 9-cis retinoic acid (Ro 04-4079),
4-oxo-9-cis retinoic acid (Ro 47-8078) and 13-cis acitretin (Ro 13-
7652) were kindly provided by Hoffmann-La Roche (Basel,
Switzerland). The compounds were dissolved in methanol and the
stock solutions were stored at –70˚C. The internal standard (IS),
13-cis acitretin 3 µ g ml–1, was prepared in aliquots and stored at
–70˚C. Working solutions of the retinoids for HPLC were obtained
by sequential dilutions of the respective stock solutions in
methanol at the time for analysis. Methanol, acetonitrile and
tetrahydrofuran were of HPLC grade and were supplied, together
with all other analytical grade reagents (glacial acetic acid, diethyl
ether, ethyl acetate) and buffers, from Merck (Darmstadt
Germany). Water for HPLC was prepared by a Milli-Q-Water
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purification system. All handling of retinoids and biological
samples was performed protected from light. Plasma samples were
stored at –70˚C for less than 3 weeks before analysis. 
Pharmacokinetic study 
Male Sprague-Dawley rats (B&K Universal, Sollentuna, Sweden)
with the average weight of 250 g were given a single intravenous
or oral dose of 9-cis RA 30–45 mg kg–1. 9-cis RA was dissolved in
DMSO (Sigma, St Louis, USA) to the concentration of 60 mg
ml–1, and then diluted 1:10 (v/v to 6 mg ml–1) in phosphate-
buffered saline (Gibco Brl, Paisley, Scotland, UK) with 1% of fetal
bovine serum (Gibco Brl), before 1.5 ml was orally or intra-
venously administrated. 
Blood collection and extraction procedures 
Blood was collected by cardiac exsanguination in tubes contain-
ing sodium heparin (100 IU ml–1, 0.05 ml ml–1 whole blood,
Karolinska Pharmacy, Sweden). Two animals were sacrificed at
each time point. Samples were collected from untreated animals
and from post injection of 9-cis RA (15 min to 8 hours). The blood
was immediately centrifuged and plasma was stored at –70˚C until
analysis, which was performed within 3 weeks from sampling. 
In a 10 ml glass tube, 25 µ l of the internal standard was added.
After addition of 0.5 ml plasma and 0.1 ml phosphate buffer, pH 7,
(0.025 M KH2PO4 and 0.04 M Na2HPO4*2H2O) the compounds
were extracted for 5 min with 3 ml of a diethyl ether-ethyl acetate
(50/50, v/v) mixture by vortex mixing. After centrifugation at
2000 g for 10 min at 4˚C, the organic phase was evaporated to
dryness. The residue was dissolved in 90 µ l methanol and trans-
ferred to an injection vial with cap, for HPLC analysis. 
Chromatographic conditions 
HPLC analysis was performed using a LKB 2150 pump equipped
with an auto sampler (Perkin-Elmer ISS-100) and a variable-
wavelength UV detector Spectromonitor (LDC/Milton Roy). The
analytical column, a Prodigy ODS (3) silica column (150 × 4.6
mm) with 3 µ m particles (Phenomenex, California, USA) was
fitted with a guard column (Nova-Pak C18, Waters, USA). Data
were acquired and analysed using System Gold (Beckman
Instruments Inc). An isocratic gradient was prepared with the final
composition of 52.87% methanol, 28.47% acetonitrile, 16.66%
water, 1.66% tetrahydrofuran and 0.34% acetic acid. The mobile
phase was degassed by ultrasonic treatment before HPLC analysis.
The flow rate was 1 ml min–1 and the UV detection was carried out
at 350 nm. A 65 µ l aliquot of each sample was auto-injected and
data were collected during 30 min. The total time between injec-
tions was 32 min. 
Calibration and system validation 
Standard curves were prepared in plasma, covering the expected
retinoid concentrations. Control plasma was spiked with known
concentrations of 9-cis RA, 4-oxo-9-cis RA and internal standard
(13-cis acitretin) in the range of 0.01 to 25.6 µ g ml–1 plasma, in
duplicate. The recovery was determined in duplicate and calculated
from peak heights, of non-extracted and extracted samples of 9-cis
RA and 4-oxo-9-cis RA. Calibration graphs and analysis of linearity
were performed by linear least-squares regression analysis, plotting
peak-height ratios of the compound and the internal standard against
the concentration of the compound. We used an external standard
containing known concentrations of the retinoids and IS to check
the day-to-day and the within-day reproducibility and variation,
concerning the retention times and the peak heights. 
Neuroblastoma cells 
The adrenergic neuroblastoma cell line SH-SY5Y was kindly
provided by Dr June Biedler, The Memorial Sloan-Kettering
Cancer Center, New York (Biedler et al, 1973). The cells were
grown at 37˚C in a humidified 95% air/5% CO2 atmosphere.
Eagle’s minimum essential medium was supplemented with 10%
fetal bovine serum, L-glutamine 2 mM, penicillin G 100 IU ml–1
and streptomycin 100 µ g ml–1 obtained from Gibco Brl. The
medium was changed twice a week and confluent cultures were
subcultivated after treatment with 0.5 g l–1 trypsin and 0.2 g l–1
EDTA (Gibco Brl). Cultures were free from mycoplasma as
detected by DNA staining. For subcutaneous injections, a single
cell suspension, 100 × 106 cells ml–1, was prepared in culture
medium supplemented with L-glutamine (2 mM). The viability
and the cell concentration were calculated by trypan blue dye
exclusion using a haematocytometer. 
Nude rats 
21 male nude rats (HsdHan: RNU-rnu, Harlan Netherlands) were
used for xenografting at the age of 5–6 weeks with an approximate
weight of 150–200 g. No animal was excluded from the study,
with the exclusion criteria applied, namely development of an
open wound over the tumour. 
Ethics 
The experiments described herein were approved by the regional
ethics committee for animal research. They also met the ethical
standards required by the United Kingdom Co-ordinating
Committee on Cancer Research (UKCCCR) Guidelines (1998). 
Xenografting 
Establishment of neuroblastoma xenografts was performed as
previously described (Nilsson et al, 1993). In short, animals were
anaesthetised with Hypnorm (Janssen Pharmaceutica, Beerse,
Belgium). Twenty million cells suspended in 0.2 ml medium were
injected in each hind leg. At injection a 23-gauge cannula was
used to deposit the suspension subcutaneously. The procedure was
carefully performed, not to pierce the muscle fascia, and not to
lose cells by leakage from the injection site. A small delineated
wheal appeared at the injection site. 
Quantification of tumour growth 
When tumour take was evident on palpation and/or visible, the
tumour length (along the tumour long axis) and width (perpendic-
ular to the long axis) were measured with a calliper every second
day. Tumour volume was calculated by length × width2 × 0.44
(Wassberg et al, 1997). The true tumour weight was recorded at
autopsy. Tumour volume index was calculated using the measured
volume divided with the volume measured at tumour take at start
of treatment. 2006 F Ponthan et al
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Retinoid treatments 
When a tumour in an animal reached a volume of 0.3 ml (designated
day 0), the rat was randomised into one of two groups, and treatment
was started. Only those tumours that had reached a volume of 0.3 ml
when treatment was started were followed and evaluated for
response. All treatments were administered with a gastric feeding
tube. In the first set of rats, 7 animals (10 tumours) were continu-
ously treated orally during 12 days with 2 mg of 9-cis retinoic acid
suspended in 1.5 ml of peanut oil. Another 7 animals (11 tumours)
received 1.5 ml peanut oil for 12 days, as a control vehicle. 
In the following therapeutic experiment a second set of rats, 4
animals (3 tumours, one rat did not develop tumours within reason-
able time) were continuously treated orally twice a day during 10
days with 2.5 mg of 9-cis retinoic acid suspended in 1.5 ml of peanut
oil. The time gap between the administrations was 8–12 hours.
Another 4 animals (4 tumours), received 2 × 1.5 ml peanut oil for 10
days, as a control vehicle. Hence, in order to have a fully comparable
control group for each treatment group, there were 2 control groups
necessary. All animals were monitored for signs of toxicity including
weight loss, yellowness and diarrhoea during treatment. 
Statistics and pharmacokinetic analysis 
Statistical analysis was performed using Mann–Whitney U test for 2
independent samples and Kruskal–Wallis test with multiple compar-
isons for more than 2 groups. Concentration–time data for 9-cis
RA and its metabolite (4-oxo-9-cis RA) were adjusted to a one-
compartment open model using Gauss–Newton (Levenberg–Hartly)
criteria. Parameters such as the distribution volume of the central
compartment, the elimination rate constant, the plasma maximum
concentration and the microconstants were estimated. Whereas,
the clearance (CI) and the distribution volume at steady-state
were calculated from the primary parameters. The area under the
plasma concentration versus time curve (AUC) was calculated
from the model-derived parameters and the elimination half-life
was calculated from the slope of the phase of elimination. The
pharmacokinetic modelling was performed using WinNonlin
version 3.0 (Pharsight, Mountain View, CA, USA). 
RESULTS 
Retinoid extraction and HPLC retinoid separation 
The analytical method used, provided the simultaneous determina-
tion of plasma concentrations of 9-cis RA, 4-oxo-9-cis RA and the
internal standard 13-cis acitretin (Figure 1). The method showed
linearity for the concentrations of 9-cis RA in the range of 0.01
to 25.6 µ g ml–1 plasma. The correlation coefficients for the
compounds were 0.9922 and 0.9984, respectively, and the inter-
cepts of the calibration curves did not differ significantly from
zero. Each concentration was determined in duplicate according to
the described method. Recovery was calculated by comparing the
measured peak height of these compounds of spiked plasma to
those of the standard solutions. The extraction recovery for 9-cis
RA was 95 ± 14% and for the metabolite 83 ± 3%. All samples
were analysed within 3 weeks from sampling, and repeated
analysis of the same sample during this period of time yielded
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Figure 1 Typical chromatogram obtained from a sample containing 4-oxo-9-cis RA, 4 µ g ml–1 (1), 13-cis acitretin, 1.5 µ g ml–1 (2) and 9-cis RA, 4 µ g ml–1 (3)identical results. In additional experiments we found that the
retinoid concentrations decreased considerably when stored for a
longer time than 3 weeks and disappeared after more than 3
months of storage (data not shown). 
Pharmacokinetics 
The pharmacokinetic parameters obtained from 9 mg 9-cis RA
given i.v. and p.o. are compiled in Table 1. After oral administra-
tion of 9 mg 9-cis RA, the ratio AUC (4-oxo-9-cis RA)/AUC (9 cis
RA) was 0.42 (Figure 2A). The same ratio after intravenous injec-
tion was 0.08 (Figure 2B). The bioavailability was 11% after oral
administration. The elimination half-life (t1/2) of 9-cis RA was 35
min (in the range 26–43 min), whereas the t1/2 of the metabolite (4-
oxo-9-cis RA) was 2.1 hours (in the range 2.10–2.15 h). Cmax (9-cis
RA) after oral dose was 2996 ng ml–1 and was reached after 1.1
hours (Tmax). The metabolite had reached its maximum levels
(Cmax,i.v. = 738 ng ml–1, Cmax,p.o. =441 ng ml–1) after 3.9 hours (in the
range 3.13–4.58 h). The distribution volume was 35.5 ml. The
clearance was 0.11 ml h–1 and 1.43 ml h–1 for 9-cis RA and 4-oxo-
9-cis RA, respectively. 
Treatment effects on tumour volume 
Neuroblastoma xenografts treated with 9-cis RA 2 mg day–1 showed
no significant reduction in tumour volume compared to control
tumours from untreated rats (Figure 3). Neuroblastoma xenografts
treated with 2.5 mg of 9-cis RA twice daily showed a significant
difference compared to corresponding controls in reduced tumour
volumes at day 10 (P < 0.05) but not at day 8 (Figure 3). 
Treatment effects on tumour weight 
Tumours from 9-cis retinoic acid treated rats, regardless of treat-
ment schedule, showed no significant reduction in tumour weight
after 10–12 days of therapy compared to untreated control tumours
(Figure 4). There was no significant difference between using the 2
mg day–1 or 2.5 mg twice daily. However, there was a tendency
towards a reduction in tumour weights in the 2 × 2.5 mg day–1
treated group. 
Bioavailability and anti-neuroblastoma effects of 9-cis RA 2007
British Journal of Cancer (2001) 85(12), 2004–2009 © 2001 Cancer Research Campaign
0
500
1000
1500
2000
2500
3000
3500
4000
100
0
200
300
400
500
600
700
800
Time (h)
9
- c i s
 
R
A
 
(
n
g
 
m
l
−
1
)
4
-
o
x
o
 
9
- c i s
 
R
A
 
(
n
g
 
m
l
−
1
)
0 12345678
20˚000
0
40˚000
60˚000
80˚000
100˚000
120˚000
140˚000
012345678
0
4000
8000
12 000
16 000
20 000
24 000
28 000
Time (h)
9
- c i s
 
R
A
 
(
n
g
 
m
l
−
1
)
4
-
o
x
o
 
9
- c i s
 
R
A
 
(
n
g
 
m
l
−
1
)
0
1
2
3
4
5
6
7
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
m
l
)
0 2 4 6 8 10 12
Days
RA 1 (9-cis 2 mg)
CTRL 1
RA 2 (9-cis 2 x 2.5 mg)
CTRL 2
RA 1 CTRL 1 RA 2 CTRL 2
0
2
4
6
8
10
12
n              10                      11                         3                         4
Median   2.79 g               2.58 g                  1.84 g                3.37 g
Range    1.49–9.98 g       0.45–6.76 g          0.92–2.95 g       2.01–7.19 g  
(9-cis 2 mg)                                (9-cis 22.5 mg)
T
u
m
o
u
r
 
w
e
i
g
h
t
 
(
g
)
Figure 2A Plasma concentration-time curves of 9-cis RA (solid line,   ) and
4-oxo-9-cis RA (dashed line,   ) after one oral dose of 9 mg 9-cis RA
Figure 2B Plasma concentration-time curves of 9-cis RA (solid line,   ) and
4-oxo-9-cis RA (dashed line,   ) after one intravenous dose of 9 mg 9-cis RA 
Figure 3 Neuroblastoma SH-SY5Y xenograft tumour volume in nude rats
treated with 9-cis RA. Mean volumes at tumour take (day 0) and 2–12 days
from start of treatment in 4 different groups: tumours from, 9-cis RA
2 mg day–1 treated rats (RA 1,   ), and corresponding control rats (CTRL 1,
   ). Tumours from, rats treated with 9-cis RA 2 × 2.5 mg (RA 2,   ), and
corresponding control rats (CTRL 2,    ). Tumour volumes for rats treated with
9-cis RA 2.5 mg twice daily were significantly smaller than for untreated rats
at day 10 (P < 0.05), but not at day 8
Figure 4 Neuroblastoma SH-SY5Y xenograft tumour weight at sacrifice
10–12 days from tumour take and start of 9-cis RA treatment in 4 different
groups: tumours from 9-cis RA 2 mg day–1 treated rats (RA 1,   ), and
corresponding control rats (CTRL 1,    ). Tumours from 9-cis RA 2 × 2.5 mg
treated rats (RA 2,   ), and corresponding control rats (CTRL 2,    ). There
were no significant differences in tumour weights comparing the retinoid
treated rats with untreated controlsToxic side effects correlated to treatment 
There were no signs of any toxicity in either of the treatment
groups. All animals irrespective of treatment showed a normal
weight gain both before and after tumour take (day 0) (Figure 5). 
DISCUSSION 
Several retinoids have shown significant effects on neuroblastoma
cells in vitro and in vivo. It has also been shown that dose sched-
uling and toxic side effects may limit the clinical application of
retinoids in children with neuroblastoma. The aim of the present
study was to investigate the kinetics and the anti-tumour effect of 9-
cis RA in order to establish the correlation between treatment effi-
cacy and dose scheduling. There are several methods available to
separate and determine retinoids (Lefebvre et al, 1995; Disdier et al,
1996; Lanvers et al, 1996). The adapted method described by us
provided the sensitivity and selectivity suitable for our purposes.
The use of both an internal and an external standard, made our
HPLC analysing method more stable concerning alterations in the
extraction procedure, surrounding temperature and fluctuations in
the mobile phase. Furthermore, analysing the samples within 3
weeks prevented
inaccurate results due to too long storage. 
The pharmacokinetic analysis showed a low bioavailability of
9-cis RA (11%). We also observed that the conversion of 9-cis RA
to its metabolite (4-oxo-9-cis RA) was about 8% after the intra-
venous dose, while the conversion was 42% after the oral dose.
Hence, when comparing the AUC of the metabolite after i.v.
versus p.o. administration (Table 1), the formed amount of 4-oxo-
9-cis RA after intravenous administration was only 2-fold higher
compared to that obtained after the oral dose. This may be due to a
limited metabolic capacity in the liver, and/or differences in the
tissue distribution after i.v. administration compared to that found
after p.o. administration (Disdier et al, 2000). The low bioavail-
ability is most probably due to the low absorption in the gastric
tract, rather than first path effect. Eckhoff et al have shown that the
molecular form of vitamin A and retinyl acetate did not play a
major role in the metabolic transformation to more polar metabo-
lites (Eckhoff et al, 1991). However, the authors found a higher
metabolic formation rate after administration of retinoids encapsu-
lated in detergent-based vehicles compared to oil-encapsulated
vehicles. In our therapeutic study we used 9-cis retinoic acid
solved in peanut oil, since retinoids used in the clinic are adminis-
trated in oiled based forms. 
Retinoic acid, in particular 13-cis retinoic acid and all-trans
retinoic acid, has been reported to induce differentiation of
neuroblastoma cells under experimental conditions in vitro and in
vivo (Sidell, 1982; Abemayor, 1992; Redfern et al, 1995). Other
studies have shown that 9-cis retinoic acid can induce both differ-
entiation and/or apoptosis in neuroblastoma cells in vitro (Redfern
et al, 1995; Lovat et al, 1997). The clinical use of retinoic acid has
mainly focused on treatment of minimal residual disease (MRD).
13-cis retinoic acid given at high-dose pulses to children with
MRD of high-risk neuroblastoma, has a significant favourable
therapeutic effect (Matthay et al, 1999). However, a randomised
study on 13-cis RA given at continuous low doses to a similar
group of patients demonstrated no survival advantages (Kohler
et al, 2000). The preclinical and clinical data on 13-cis RA used
against neuroblastoma indicate that dosing, scheduling, timing and
tumour load at start of treatment may all be important elements in
determining the therapeutic efficacy of 13-cis RA (Matthay and
Reynolds, 2000). These elements concerning 13-cis RA, may also
be important in developing a successful treatment of neuroblas-
toma with other retinoids such as 9-cis RA. 
In our previous study we found that 3 different retinoids signifi-
cantly decreased tumour growth of human SH-SY5Y neuroblas-
toma xenografts in nude rats (Ponthan et al, 2001). However, the
high dose of 9-cis RA used in that study (5 mg once daily),
2008 F Ponthan et al
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Figure 5 The relative change in body weight during continuous treatment
with 9-cis RA or the control treatment peanut oil. The 4 different treatment
groups were: 9-cis RA 2 mg day–1 treated rats (RA 1,   ), and corresponding
control rats (CTRL 1,    ). Rats treated with 9-cis RA 2 × 2.5 mg (RA 2,   ),
and corresponding control rats (CTRL 2,    ). Rats, regardless of treatment
schedule, gained in weight before and during treatment
Table 1 Pharmacokinetic parameters of 9-cis retinoic acid in rat. 
Oral administrationa Intravenous administrationa
9-cis RA 4-oxo-9-cis RA 9-cis RA 4-oxo-9-cis RA 
AUCb (ng ml–1 h–1) 8548 3563 80091 6295 
T1/2
c (h) 0.71 2.1 0.44 2.15 
CId (ml h–1) 0.11 1.43 
Cmax
e (ng ml–1) 2996 441 120476 738 
Tmax
f (h) 1.05 4.58 3.13 
a9 mg 9-cis RA given p.o. or i.v. according to Materials and Methods. bAUC = area under the curve. 
cT1/2 = elimination half-life. dCl = clearance. eCmax = concentration maximum. fTmax = time of Cmax. Bioavailability and anti-neuroblastoma effects of 9-cis RA 2009
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resulted in major toxic side effects, such as weight loss, yellowish
colour, dry skin and diarrhoea. The main focus of our present
study was to analyse the bioavailability of 9-cis RA. Furthermore,
we investigated whether changes in doses and treatment sched-
uling could reduce the toxic side effects with retained tumour-
inhibiting effect. For these in vivo studies we used individual
control groups for each therapeutic experiment to eliminate the
possible differences in tumour growth which may be caused by
environmental alterations concerning cell culturing and animal
breeding. 
When the daily dose of 9-cis RA was reduced to 2 mg day–1, no
signs of toxicity were observed (Figure 5). However, the tumour
growth-inhibiting effect was not significant compared to corre-
sponding placebo-treated controls. By altering the scheduling of
the toxic but tumour effective dose 5 mg day–1 by giving 2.5 mg
twice daily no signs of toxicity could be detected (Figure 5). The
absence of toxicity after dividing the daily dose indicates that the
toxicity from 9-cis RA is mainly depending on the peak concentra-
tion (Cmax). The altered scheduling resulted in a limited but statisti-
cally significant reduction in tumour growth, in terms of tumour
volume at end of treatment (Figure 3). Tumour weights showed no
significant difference when comparing the group treated with 9-cis
RA 2.5 mg twice daily to the corresponding untreated control
tumours (Figure 4). Because of the tendency towards a reduction
in tumour weights we compared the 2 × 2.5 mg day–1 treated
tumours with all control tumours taken together. However, this
statistical comparison did not show a significant difference in
tumour weights. The limited effects, if any, on both tumour
volumes and tumour weights using the divided dose could argue
that the AUC of 9-cis RA only has a limited influence on the
tumour inhibiting effect of the retinoid. It seems likely that the
peak concentration (Cmax) is important for the tumour growth
inhibiting effect of 9-cis RA. 
Combining the results from these experiments on 3 different
treatment schedules used in the current and the previous study
(Ponthan et al, 2001), we conclude that 9-cis RA may reduce
tumour growth in vivo in a dose-dependent manner. However, the
toxicity profile, the short half-life and the low bioavailability of
9 cis RA in vivo, limit the potential use for clinical oral therapy of
neuroblastoma in children. 
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